Investigational drug · Phase 2
AVZO-1418
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors.
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "AVZO-1418"
First trial start
2025
Jun 4, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AVZO-1418", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumor Cancer
- Locally Advanced
- Metastatic Solid Tumors
- Lung Cancers
- Epithelial Tumor
- Biliary Tract Cancer (BTC)
- Urothelial Cancer
- Nasopharyngeal Cancers
Approved drugs for the same conditions: Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "AVZO-1418" as an intervention, largest first.
Avenzo Therapeutics, Inc.Industry
NCT07038343 · 480 participants (planned) · Start Jun 4, 2025 · Primary completion Jun 2030
Drug: AVZO-1418; Combination Agent 1 and 1 more · For: Solid Tumor Cancer; Locally Advanced; Metastatic Solid Tumors and 5 more
Sites: Gilbert, Arizona; Los Angeles, California; Denver, Colorado · 27 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Solid Tumor Cancer
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- RNK08954Phase 23 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor Cancer, PDAC, KRAS G12D Mutations
- AD1208Phase 21 trial
Avelos Therapeutics Inc. · Solid Tumor, Adult, Tumor, Solid, Solid Tumor
- AVZO-103Phase 21 trial
Avenzo Therapeutics, Inc. · Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.